A randomized, placebo-controlled trial of the BTK inhibitor zanubrutinib in hospitalized patients with COVID-19 respiratory distress: immune biomarker and clinical findings is a research paper published in Frontiers in Immunology (2025). On theSindex it has a DataRank of 0.343. It has been cited 7 times, with 6 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.312
From this paper's citation signal
Citation Network Contribution
0.0310
From 1 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 6 citers.
NCI NIH HHS
Grant: R50 CA251956
NHLBI NIH HHS
Grant: R01 HL157174
NCI NIH HHS
Grant: P50 CA100707
National Institutes of Health
Grant: 2P50CA100707-16A1
SPORE in Multiple Myeloma
Leukemia and Lymphoma Society
National Institutes of Health
FWCI
4.94
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals